Latham & Watkins Advises VistaGen Therapeutics, Inc. in US$100 Million Underwritten Public Offering

VistaGen Therapeutics, Inc. (VistaGen), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system disorders, has announced the closing of its previously announced underwritten public offering of 63 million shares of its common stock, at an offering price of US$.92 per share, and 2 million shares of its newly created Series D convertible preferred stock, at a public offering price of US$21.16 per share. The gross proceeds to VistaGen from the offering, before deducting underwriting discounts and commissions and offering expenses, were US$100 million.

Latham & Watkins LLP represented VistaGen in the transaction with a capital markets team led by partners Christopher Lueking and Nathan Ajiashvili, with associates Scott Westhoff, Jonathan Sarna, Sara Mykrantz and Omeed Valipour. Advice was also provided on regulatory matters by partner Elizabeth Richards and counsel Betty Pang, with associates Barrett Tenbarge and Julie Shin; on data privacy matters by counsel Heather Deixler; on intellectual property matters by partner Chris Hazuka, with associate Peggy Ni; and on tax matters by partner Joseph Kronsnoble, with associate Christopher Ohlgart.